AU
CA
NZ
UK
US
IND
Last update at 2026-03-10T20:13:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying
Thu 22 May 25, 02:06 PMSanofi to acquire Vigil Neuroscience in Alzheimer’s drug play
Thu 22 May 25, 12:22 AMFrench finance minister criticises Sanofi's $20 billion USA investment decision
Thu 15 May 25, 04:55 PMSanofi commits ‘at least $20bn’ to US manufacturing through 2030
Thu 15 May 25, 11:47 AMFrance's Sanofi to invest at least $20 billion in US through 2030
Wed 14 May 25, 04:42 PMSanofi (SNY): A Bull Case Theory
Tue 13 May 25, 03:15 PMNVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up
Fri 09 May 25, 12:55 PMCOVID Vaccine Maker Novavax Stock Soars 16% - Here's Why
Thu 08 May 25, 05:31 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 8268.00M | 7798.00M | 13804.00M | 2822.00M | 4405.00M |
| Minority interest | -113.00000M | -56.00000M | 146.00M | 174.00M | 159.00M |
| Net income | 6720.00M | 6223.00M | 12314.00M | 2806.00M | 4306.00M |
| Selling general administrative | 10492.00M | 9555.00M | 9390.00M | 9883.00M | 9859.00M |
| Selling and marketing expenses | - | - | 9390.00M | 9883.00M | 9859.00M |
| Gross profit | 31694.00M | 26920.00M | 25212.00M | 25655.00M | 24242.00M |
| Reconciled depreciation | 2053.00M | 1580.00M | 3684.00M | 7452.00M | 4279.00M |
| Ebit | 11717.00M | 8126.00M | 8082.00M | 7694.00M | 6921.00M |
| Ebitda | 13770.00M | 10762.00M | 9763.00M | 9840.00M | 9091.00M |
| Depreciation and amortization | 2053.00M | 2636.00M | 1681.00M | 2146.00M | 2170.00M |
| Non operating income net other | - | - | - | 0.00000M | 0.00000M |
| Operating income | 11717.00M | 8126.00M | 8082.00M | 7694.00M | 4676.00M |
| Other operating expenses | 33508.00M | 30028.00M | 29476.00M | 30405.00M | 29422.00M |
| Interest expense | 440.00M | 368.00M | 390.00M | 444.00M | 435.00M |
| Tax provision | 1503.00M | 1558.00M | 1813.00M | 139.00M | 481.00M |
| Interest income | 206.00M | 40.00M | 53.00M | 141.00M | 164.00M |
| Net interest income | -234.00000M | -328.00000M | -337.00000M | -303.00000M | -271.00000M |
| Extraordinary items | - | - | - | -101.00000M | -13.00000M |
| Non recurring | - | - | - | 0.00000M | 0.00000M |
| Other items | - | - | - | 0.00000M | 0.00000M |
| Income tax expense | 1503.00M | 1558.00M | 1813.00M | 139.00M | 481.00M |
| Total revenue | 45389.00M | 39175.00M | 37369.00M | 37631.00M | 35677.00M |
| Total operating expenses | 19813.00M | 17773.00M | 17319.00M | 18429.00M | 17987.00M |
| Cost of revenue | 13695.00M | 12255.00M | 12157.00M | 11976.00M | 11435.00M |
| Total other income expense net | -3449.00000M | -328.00000M | 5722.00M | -4872.00000M | -1579.00000M |
| Discontinued operations | - | - | - | -101.00000M | -13.00000M |
| Net income from continuing ops | 6833.00M | 6279.00M | 12350.00M | 2938.00M | 4423.00M |
| Net income applicable to common shares | 8371.00M | 6223.00M | 12314.00M | 2806.00M | 4306.00M |
| Preferred stock and other adjustments | - | - | - | 0.00000M | 0.00000M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 132798.00M | 126464.00M | 124585.00M | 120242.00M | 114529.00M |
| Intangible assets | 22629.00M | 73573.00M | 21640.00M | 21407.00M | 18421.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 14601.00M | 1239.00M | 85.00M | 89.00M | 83.00M |
| Total liab | 54941.00M | 52111.00M | 51073.00M | 51211.00M | 51382.00M |
| Total stockholder equity | 77507.00M | 74040.00M | 73144.00M | 68681.00M | 63001.00M |
| Deferred long term liab | - | - | 6226.00M | 7730.00M | 6092.00M |
| Other current liab | 16007.00M | 13949.00M | 425.00M | 127.00M | 32.00M |
| Common stock | 2526.00M | 2530.00M | 2522.00M | 2527.00M | 2518.00M |
| Capital stock | 2526.00M | 2530.00M | 2522.00M | 2527.00M | 2518.00M |
| Retained earnings | - | 67499.00M | - | - | - |
| Other liab | - | - | 10835.00M | 10954.00M | 11426.00M |
| Good will | 43384.00M | 49404.00M | 49892.00M | 48056.00M | 44364.00M |
| Other assets | - | - | 12856.00M | 13455.00M | 11358.00M |
| Cash | 7441.00M | 8710.00M | 12736.00M | 10098.00M | 13915.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 29162.00M | 24194.00M | 23974.00M | 21295.00M | 19280.00M |
| Current deferred revenue | - | 597.00M | 264.00M | 319.00M | 822.00M |
| Net debt | 10465.00M | 9712.00M | 8476.00M | 12316.00M | 9760.00M |
| Short term debt | 4470.00M | 2320.00M | 4451.00M | 3452.00M | 2999.00M |
| Short long term debt | 4209.00M | 2045.00M | 4174.00M | 3183.00M | 2767.00M |
| Short long term debt total | 17906.00M | 18422.00M | 21212.00M | 22414.00M | 23675.00M |
| Other stockholder equity | 4420.00M | -871.00000M | 2437.00M | 3998.00M | 3795.00M |
| Property plant equipment | - | - | 11684.00M | 11976.00M | 10563.00M |
| Total current assets | 42588.00M | 30655.00M | 34111.00M | 30653.00M | 33786.00M |
| Long term investments | 3259.00M | 2666.00M | 9153.00M | 7975.00M | 7147.00M |
| Net tangible assets | - | - | 9478.00M | 6948.00M | 6308.00M |
| Short term investments | 486.00M | 270.00M | 664.00M | 1054.00M | 900.00M |
| Net receivables | 10629.00M | 11040.00M | 374.00M | 612.00M | 1208.00M |
| Long term debt | 11791.00M | 14347.00M | 14857.00M | 17123.00M | 19745.00M |
| Inventory | 9431.00M | 9666.00M | 20916.00M | 19854.00M | 18580.00M |
| Accounts payable | 7551.00M | 7328.00M | 18834.00M | 17397.00M | 15427.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 70561.00M | 4882.00M | 68185.00M | 62156.00M | 56688.00M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | 2518.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1370.00M | 738.00M | -5139.00000M | -4423.00000M | -3964.00000M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 90210.00M | 95809.00M | 90474.00M | 89589.00M | 80743.00M |
| Capital lease obligations | 1906.00M | 2030.00M | 2181.00M | 2108.00M | 1163.00M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -2075.00000M | -311.00000M | 10233.00M | -1058.00000M | -12872.00000M |
| Change to liabilities | 452.00M | 451.00M | 86.00M | 169.00M | 270.00M |
| Total cashflows from investing activities | -2075.00000M | -7298.00000M | 3588.00M | -1212.00000M | -12866.00000M |
| Net borrowings | -1245.00000M | -2804.00000M | -1885.00000M | -491.00000M | 8722.00M |
| Total cash from financing activities | -5821.00000M | -7056.00000M | -6485.00000M | -4039.00000M | 3928.00M |
| Change to operating activities | 545.00M | 1130.00M | 316.00M | 421.00M | -814.00000M |
| Net income | 8371.00M | 6223.00M | 12294.00M | 2754.00M | 4306.00M |
| Change in cash | 2638.00M | -3817.00000M | 4488.00M | 2502.00M | -3390.00000M |
| Begin period cash flow | 10098.00M | 13915.00M | 9427.00M | 6925.00M | 10315.00M |
| End period cash flow | 12736.00M | 10098.00M | 13915.00M | 9427.00M | 6925.00M |
| Total cash from operating activities | 10526.00M | 10522.00M | 7418.00M | 7715.00M | 5547.00M |
| Issuance of capital stock | 188.00M | 186.00M | 203.00M | 162.00M | 177.00M |
| Depreciation | 3365.00M | 3001.00M | 3186.00M | 3593.00M | 3339.00M |
| Other cashflows from investing activities | -16.00000M | -68.00000M | -113.00000M | -94.00000M | -58.00000M |
| Dividends paid | -4168.00000M | -4008.00000M | -3937.00000M | -3834.00000M | 3773.00M |
| Change to inventory | -927.00000M | -357.00000M | -593.00000M | -547.00000M | -701.00000M |
| Change to account receivables | -777.00000M | 185.00M | -134.00000M | -462.00000M | -35.00000M |
| Sale purchase of stock | -497.00000M | -382.00000M | -822.00000M | -9.00000M | -1101.00000M |
| Other cashflows from financing activities | 1665.00M | -462.00000M | 2257.00M | 1976.00M | 7701.00M |
| Change to netincome | -600.00000M | -230.00000M | -7851.00000M | 1630.00M | -933.00000M |
| Capital expenditures | 1606.00M | 1479.00M | 1254.00M | 1323.00M | 1415.00M |
| Change receivables | - | - | - | 0.00000M | 0.00000M |
| Cash flows other operating | - | - | - | 0.00000M | 0.00000M |
| Exchange rate changes | - | - | - | 0.00000M | 0.00000M |
| Cash and cash equivalents changes | - | - | - | 0.00000M | 0.00000M |
| Change in working capital | -1704.00000M | 1409.00M | -325.00000M | -419.00000M | -1280.00000M |
| Stock based compensation | 245.00M | 244.00M | 274.00M | 252.00M | 284.00M |
| Other non cash items | 827.00M | 1.00M | -7797.00000M | 3288.00M | -2098.00000M |
| Free cash flow | 8920.00M | 9043.00M | 6164.00M | 6392.00M | 4132.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SNY Sanofi ADR |
-0.38 0.86% | 43.97 | 18.52 | 11.27 | 2.80 | 1.53 | 2.77 | 12.41 |
| LLY Eli Lilly and Company |
-7.04 0.70% | 1001.35 | 78.14 | 31.95 | 16.34 | 45.83 | 16.65 | 54.36 |
| JNJ Johnson & Johnson |
1.12 0.46% | 243.71 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| ABBV AbbVie Inc |
-0.44 0.19% | 227.01 | 61.52 | 14.86 | 5.62 | 51.62 | 6.76 | 20.58 |
| MRK Merck & Company Inc |
-0.02 0.02% | 117.09 | 59.83 | 12.33 | 4.50 | 6.47 | 4.94 | 23.79 |
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
46, avenue de la Grande Armée, Paris, France, 75017
| Name | Title | Year Born |
|---|---|---|
| Mr. Paul Hudson | CEO & Director | 1967 |
| Mr. Jean-Baptiste Chasseloup de Chatillon | Exec. VP & CFO | 1965 |
| Mr. Laurent Gilhodes | Principal Accounting Officer and VP of Corp. Accounting | NA |
| Mr. Bruno Ménard | Chief Information officer | NA |
| Dr. Josephine Fubara | Chief Science Officer of Consumer Health Care | NA |
| Eva Schaefer-Jansen | Head of Investor Relations | NA |
| Mr. Dante Beccaria | Global Compliance Officer & VP | NA |
| Mr. Roy Papatheodorou | Exec. VP, Gen. Counsel and Head of Legal, Ethics & Bus. Integrity | 1978 |
| Mr. Josep Catlla | Head of Communications | NA |
| Mr. Pierre Chancel | Sr. VP of Global Diabetes and Sr. VP of Global Marketing | 1957 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...